Skip to main content
SpringerLink
Log in

Onkologie II

  • Conference paper
Handbuch HNO 2009

Part of the book series: Handbuch Update-Seminar ((UPDATESEMINAR))

  • 1947 Accesses

Zusammenfassung

Die Hoffnung, die seit Jahrzehnten nicht relevant verbesserten Gesamtüberlebensraten von Patienten mit Karzinomen des Kopf- und Halsbereiches zu verbessern, ruht im Wesentlichen auf der weiteren Optimierung der strahlentherapeutischen und auch medikamentösen therapeutischen Strategien. Hier dürfte der weitere Einsatz gegen biologische Targets gerichtete Medikamente weiter in den Fokus rücken. Der genaue Zeitpunkt der Anwendung aber auch die Kombination mit anderen therapeutischen Maßnahmen sind Gegenstand aktueller erheblicher Studienanstrengungen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. NCCN: Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network 2007: http://www.nccn.org.

  2. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350:1945–52.

    Article  CAS  PubMed  Google Scholar 

  3. Kessler P, Grabenbauer G, Leher A, Bloch-Birkholz A, Vairaktaris E, Neukam FW: Neoadjuvant and adjuvant therapy in patients with oral squamous cell carcinoma Long-term survival in a prospective, non-randomized study. Br J Oral Maxillofac Surg 2008; 46:1–5.

    Article  PubMed  Google Scholar 

  4. Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH, Geara FB, Klotch DW, Goepfert H, Peters LJ: Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 51: 571–8.

    Article  CAS  PubMed  Google Scholar 

  5. Burri RJ, Lee NY: Concurrent chemotherapy and radiotherapy for head and neck cancer. Expert Rev Anticancer Ther 2009; 9: 293–302.

    Article  PubMed  Google Scholar 

  6. Pignon JP, Baujat B, Bourhis J: [Individual patient data meta-analyses in head and neck carcinoma: what have we learnt?]. Cancer Radiother 2005; 9: 31–6.

    PubMed  Google Scholar 

  7. Pignon JP, le Maitre A, Maillard E, Bourhis J: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4–14.

    Article  PubMed  Google Scholar 

  8. Bernier J: Current state-of-the-art for concurrent chemoradiation. Semin Radiat Oncol 2009; 19: 3–10.

    Article  PubMed  Google Scholar 

  9. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48: 7–16.

    Article  CAS  PubMed  Google Scholar 

  10. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot JC, Le Maitre A, Pajak TF, Poulsen MG, O’Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay JH, Pinto LH, Fallai C, Fu KK, Sylvester R, Pignon JP: Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006; 368: 843–54.

    Article  PubMed  Google Scholar 

  11. Welz H, Pottgen C, Abu Jawad J, Wierlemann A, Wittig A, Stuben G, Budach V, Lehnerdt G, Jahnke K, Sack H, Stuschke M: Hyperfractionated accelerated radiotherapy versus conventional fractionation both combined with chemotherapy in patients with locally advanced head and neck carcinomas: a retrospective analysis of a monoinstitutional series. Oncology 2009; 76:405–12.

    Article  CAS  PubMed  Google Scholar 

  12. Huguenin P, Beer KT, Allai A, Rufibach K, Friedli C, Davis JB, Pestalozzi B, Schmid S, Thoni A, Ozsahin M, Bernier J, Töpfer M, Kann R, Meier UR, Thum P, Bieri S, Notter M, Lombriser N, Glanzmann C: Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004; 22: 4665–73.

    Article  CAS  PubMed  Google Scholar 

  13. Machtay M MJ, Trotti A: Factors associacted with severe late toxicity after concurrent chemoradiation for locally advanced head nach neck cancer: An RTOG analysis. J Clin Oncol 2008; 26: 3582–3589.

    Article  CAS  PubMed  Google Scholar 

  14. Wolff H.A. OTea: Toxicity of daliy low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer. J Cancer Res Clin Oncol 2008; 135.

    Google Scholar 

  15. Mesia R, Manos M, Nogues J, Galiana R, Martinez Garcia M, Lozano A, Tornero J, Ramon Germa J: Hyperfractionated radiotherapy: improvement of survival in locally advanced nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol 2009; 118: 442–8.

    PubMed  Google Scholar 

  16. Gupta T, Agarwal JP, Ghosh-Laskar S, Parikh PM, D’Cruz AK, Dinshaw KA: Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience. Head Neck Oncol 2009; 1:17.

    Article  PubMed  Google Scholar 

  17. L. Koutcher MF, S. Wolden, Z. Zhang, Q. Mo, M. Zelefsky, D. Kraus, E. Sherman, D. Pfister, N. Lee;: Comparison of cisplatin (CDDP) and radiation (RT) to cetuximab (C) and RT for locally advanced head and neck cancer (LAHNC): A preliminary analysis. J Clin Oncol 2009; 27.

    Google Scholar 

  18. Galper SL, H. Deshpande, M. G. Rose, R. H. Decker: Cetuximab versus cisplatin concurrent with IMRT in locally advanced head and neck cancer (LAHNC). J Clin Oncol 2009; 27.

    Google Scholar 

  19. Rojo F, Gracias, E., Villena, N., Cruz, T., Corradino, I., Cedeno, M., Campas, C, Sessa, C, Crombet, T., Albanell, J.: Pharmacodynamic study of nimotuzumab, an anti-epidermal growth factor receptor (EGRF) monoclonal antibody (MAb), in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN): A SENDO Foundation study. J Clin Oncol 2008; 26.

    Google Scholar 

  20. Krishnamurthyreddy B. MSV, R. Koteshwar, A. Shenoy, L. Viswanath, N. Thimmaiah, G. Babu, B. Joseph, R. Bonnathiya, P. P. Bapsy: A phase lib 4-arm open-label randomized study to assess the safety and efficacy of h-R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. J Clin Oncol 2009; 27.

    Google Scholar 

  21. Rodriguez C. P. DJ A, J. P. Saxton, L. A. Rybicki, R. R. Lorenz, B. G. Wood, J. Scharpf, W. T. Lee, D. I. Ives: Multiagent concurrent chemoradiotherapy (MACCRT) and gefitinib in locoregionally advanced head and neck squamous cell cancer (HNSCC). J Clin Oncol 2009; 27.

    Google Scholar 

  22. Papadimitrakopoulou V. SJF, G. R. Blumenschein, C. Chen, M. Kane, E. E. Cohen, P. Langmuir, A. D. Krebs, S. M. Lippman, D. Raben: Phase I evaluation of vandetanib with radiation therapy (RT) ± cisplatin in previously untreated advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2009; 27.

    Google Scholar 

  23. Jacobs C. GDRea: Chemotherapy as a substitute for surgery in the treatment advanced resectable head and neck cancer. A report from the Northern California Oncology Group. Cancer 1987;60(6): 1178–83. Northern California Oncology Group. Cancer 1987; 60(6): 1178-83

    Article  CAS  PubMed  Google Scholar 

  24. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T: Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996; 88: 890–9.

    Article  CAS  PubMed  Google Scholar 

  25. Richard JM, Sancho-Gamier H, Pessey JJ, Luboinski B, Lefebvre JL, Dehesdin D, Stromboni-Luboinski M, Hill C: Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol 1998; 34: 224–8.

    Article  CAS  PubMed  Google Scholar 

  26. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091–8.

    Article  CAS  PubMed  Google Scholar 

  27. Lefebvre J.L. RFea: Phase III randomized trail on larynx preservation comparing sequential versus alternating chemotherapy and radiotherapy. J Natl Cancer Inst 2009; 101:142–152.

    Article  CAS  PubMed  Google Scholar 

  28. Isla D. JM-T, S. Morales, A. Yubero, J. Lambea, I. Alvarez, E. Polo, M. A. Segui, E. Pujol, P. Pastor: A pilot study of modified neoadjuvant docetaxel/cisplatin/5-FU (TPF) to concomitant chemoradiotherapy (CT/RT) in locally advanced head and neck cancer (LAHNC): Preliminary results. J Clin Oncol 2009; 27.

    Google Scholar 

  29. Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, Guerrif S, Alfonsi M, Calais G: Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009; 101:498–506.

    Article  CAS  PubMed  Google Scholar 

  30. Hitt R. JJG, A. Lopez-Pousa, A. Berrocal, C. Garcia Giron, A. Irigoyen, J. Sastre, J. Martinez, H. Cortes-Funes, J. Cruz-Hernandez: Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol 2009; 27.

    Google Scholar 

  31. Beldjilali Y. KAB, A. Boukerche, H. Khellafi, A. Abdelaoui, F. Betkaoui, Z. K. Tourabi, M. Y. Kaïd, L. Djellali, M. Yamouni: First results of induction chemotherapy with cisplatin, docetaxel, and capecitabine for the treatment of nasopharyngeal carcinoma. J Clin Oncol 2009; 27.

    Google Scholar 

  32. Bossi P. DP, C. Bergamini, L. D. Locati, E. Orlandi, M. Franceschini, M. Palazzi, P. Olmi, P. Potepan, L. Licitra: TPF induction chemotherapy (CT) followed by concomitant cisplatin/radiotherapy (cCTRT) in locally advanced nasopharyngeal cancer (LANPC). J Clin Oncol 2009; 27.

    Google Scholar 

  33. Airoldi M, Gabriele AM, Garzaro M, Raimondo L, Condello C, Beatrice F, Pecorari G, Giordano C: Induction chemotherapy with cisplatin and epirubicin followed by radiotherapy and concurrent cisplatin in locally advanced nasopharyngeal carcinoma observed in a non-endemic population. Radiother Oncol 2009; 92:105–10.

    Article  CAS  PubMed  Google Scholar 

  34. Jordan W. IW, H. WeIkoborsky, J. Borghardt, H. Zakaria, B. Tschechne: TPF induction therapy with radioimmunochemotherapy for the treatment of head and neck cancer. J Clin Oncol 2009; 27.

    Google Scholar 

  35. Mercke C. GW-J, H. Sjödin, G. Adell, J. Nyman, H. Haugen: Upfront chemotherapy and accelerated radiotherapy with EGFR inhibition for locally advanced inoperable head and neck cancer. J Clin Oncol 2009; 27.

    Google Scholar 

  36. Meluch A. A. DS, H. A. Burris, C. Lane, J. D. Peyton, D. Shipley, M. Rubin, M. Stipanov, F. A. Greco, J. D. Hainsworth: Combined modality therapy with radiation therapy (RT), chemotherapy, bevacizumab, and erlotinib in the treatment of patients (pts) with locally advanced squamous carcinoma of the head and neck. J Clin Oncol 2009; 27.

    Google Scholar 

  37. Hainsworth JD, Spigel DR, Burris HA, 3rd, Markus TM, Shipley D, Kuzur M, Lunin S, Greco FA: Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck. Cancer 2009; 115: 2138–46.

    Article  CAS  PubMed  Google Scholar 

  38. Prades JM, Lallemant B, Garrel R, Reyt E, Righini C, Schmitt T, Remini N, Saban-Roche L, Timoshenko AP, Trombert B, Guerrier B: Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma. Acta Otolaryngol. 2009:1-6.

    Google Scholar 

  39. Nishimura G, Tsukuda M, Mikami Y, Matsuda H, Horiuchi C, Taguchi T, Takahashi M, Kawakami M, Watanabe M, Niho T, Abo H, Yamomoto S: Efficacy of concurrent chemoradiotherapy for T1 and T2 laryngeal squamous cell carcinoma regarding organ preservation. Anticancer Res. 2009; 29:661–666.

    PubMed  Google Scholar 

  40. Franchin G, Vaccher E, Politi D, Minatel E, Gobitti C, Talamini R, Spazzapan S, Savignano MG, Trovo MG, Barzan L: Organ preservation in locally advanced head and neck cancer of the larynx using induction chemotherapy followed by improved radiation schemes. Eur.Arch.Otorhinolaryngol. 2009; 266: 719–726.

    Article  PubMed  Google Scholar 

  41. Dietz A, Rudat V, Dreyhaupt J, Pritsch M, Hoppe F, Hagen R, Pfreundner L, Schroder U, Eckel H, Hess M, Schroder M, Schneider P, Jens B, Zenner HP, Werner JA, Engenhardt-Cabillic R, Vanselow B, Plinkert P, Niewald M, Kuhnt T, Budach W, Flentje M: Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-l-trial). Eur.Arch.Otorhinolaryngol. 2008.

    Google Scholar 

  42. Hancock SB, Krempl GA, Canfield V, Bogardus C, Kojouri K, Kaneaster SK, Medina JE: Treatment of base of tongue cancer with paclitaxel, ifosfamide, and cisplatinum induction chemotherapy followed by chemoradiotherapy. Laryngoscope 2008; 118:1357–1361.

    Article  CAS  PubMed  Google Scholar 

  43. Lefebvre J, Pointreau Y, Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Preliminary results of the randomized phase II TREMPLIN study. 2009: ASCO Abstract 2009.

    Google Scholar 

  44. Kao J, Policarpio M, Phase II trial of concurrent 5-fluorouracil. hydroxyurea, cetuximab and intesity moduled radiation therapy (IMRT) for locally advanced head and neck cancer. 2009: ASCO Abstract 2009.

    Google Scholar 

  45. Dijkema T, Terhaard CH, Roesink JM, Braam PM, van Gils CH, Moerland MA, Raaijmakers CP: Large cohort dose-volume response analysis of parotid gland function after radiotherapy: intensity-modulated versus conventional radiotherapy. Int J Radiat Oncol Biol Phys 2008; 72:1101–9.

    Article  PubMed  Google Scholar 

  46. Lyman JT, Wolbarst AB: Optimization of radiation therapy, III: A method of assessing complication probabilities from dose-volume histograms. Int J Radiat Oncol Biol Phys 1987; 13:103–9.

    CAS  PubMed  Google Scholar 

  47. Ortholan C, Chamorey E, Benezery K, Thariat J, Dassonville O, Poissonnet G, Bozec A, Follana P, Peyrade F, Sudaka A, Gerard JP, Bensadoun RJ: Modeling of salivary production recovery after radiotherapy using mixed models: determination of optimal dose constraint for IMRT planning and construction of convenient tools to predict salivary function. Int J Radiat Oncol Biol Phys 2009; 73:178–86.

    Article  PubMed  Google Scholar 

  48. Ho KF, Fowler JF, Sykes AJ, Yap BK, Lee LW, Slevin NJ: IMRT dose fractionation for head and neck cancer: variation in current approaches will make standardisation difficult. Acta Oncol 2009; 48: 431–9.

    Article  CAS  PubMed  Google Scholar 

  49. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116–27.

    Article  Google Scholar 

  50. Tanvetyanon T, Padhya T, McCaffrey J, Zhu W, Boulware D, Deconti R, Trotti A: Prognostic factors for survival after salvage reirradiation of head and neck cancer. J Clin Oncol 2009; 27:1983–91.

    Article  PubMed  Google Scholar 

  51. Janot F, de Raucourt D, Benhamou E, Ferron C, Dolivet G, Bensadoun RJ, Hamoir M, Gery B, Julieron M, Castaing M, Bardet E, Grégoire V, Bourhis J: Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008; 26: 5518–23.

    Article  CAS  PubMed  Google Scholar 

  52. Gilbert J, Cmelak A, Shyr Y, Netterville J, Burkey BB, Sinard RJ, Yarbrough WG, Chung CH, Aulino JM, Murphy BA: Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck. Cancer 2008; 113: 186–92.

    Article  CAS  PubMed  Google Scholar 

  53. Gilbert J, Lee J, Argiris A, Feldman L, Haigentz M, Burtness B, Forastiere A, Eastern Cooperative Oncology Group: Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol (Meeting Abstracts) 2009; 27: 6020-.

    Google Scholar 

  54. Zhang J, Lee JS, Urba S, Worden F: A phase II trial evaluating weekly docetaxel and capacitabine in patients with metastatic or advanced, locally, recurrent head and neck cancer. J Clin Oncol (Meeting Abstracts) 2009; 27: 6051-.

    Google Scholar 

  55. Li YH, Wang FH, Jiang WQ, Xiang XJ, Deng YM, Hu GQ, Xu DM, Chen Y, Lin Q, He YJ: Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol 2008; 62: 539–44.

    Article  CAS  PubMed  Google Scholar 

  56. Martinez-Trufero J, Isla D, Adansa JC, Irigoyen A, Hitt R, Lambea J, Cruz JJ: Phase II study of capecitabine as palliative treatment for patients (p) with squamous head and neck cancer (HNC) with locoregional and/or metastatic relapse after previous platinum-based treatment (PBT): Final results of Spanish Head and Neck Cancer Group (TTCC). J Clin Oncol (Meeting Abstracts) 2009; 27: 6047-.

    Google Scholar 

  57. van Herpen CM, Locati LD, Buter J, Thomas J, Bogaerts J, Lacombe D, de Mulder P, Awada A, Licitra L, Bernier J, Vermorken JB: Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). Eur J Cancer 2008; 44: 2542–5.

    Article  PubMed  Google Scholar 

  58. Caponigro F, Carteni G, Droz JP, Milano A, Davis WB, Pollard P: Phase II study of rubitecan in recurrent or metastatic head and neck cancer. Cancer Chemother Pharmacol 2008; 62: 209–14.

    Article  CAS  PubMed  Google Scholar 

  59. Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Hargreaves L, Armour A, Speake G, Swaisland A, Vokes EE: Phase III study of gefitinib 250 compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27:1864–71.

    Article  CAS  PubMed  Google Scholar 

  60. Argiris A, Ghebremichael M, Gilbert J, Burtness B, Forastiere A: A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A trial of the Eastern Cooperative Oncology Group (ECOG). J Clin Oncol (Meeting Abstracts) 2009; 27: 6011-.

    Google Scholar 

  61. Chua DT, Wei Wl, Wong MP, Sham JS, Nicholls J, Au GK: Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck 2008; 30: 863–7.

    Article  PubMed  Google Scholar 

  62. Vermorken JB, Stohlmacher J, Davidenko I, Winquist E, Licitra L, Pai VR, Skladowski K, Blajman CR, Faivre S, Gansert J: An analysis of safety in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) receiving chemotherapy (CT) with or without panitumumab (pmab) in a phase III clinical trial (SPECTRUM). J Clin Oncol (Meeting Abstracts) 2009; 27: 6050-.

    Google Scholar 

  63. Diaz de Corcuera I, Serrano C, Perez J, Quispe I, Arguis M, Munoz E, Benavente S, Martinez P, Parera M, del Campo JM: Weekly cetuximab and paclitaxel combination in metastatic/recurrent squamous cell cancer carcinoma of the head and neck (SCCHN): Clinical experience of a single institution. J Clin Oncol (Meeting Abstracts) 2009; 27: e17043-.

    Google Scholar 

  64. Knoedler MK, Gauler T, Matzdorff A, Jordan O, Schroeder M, Gruenwald V, Dietz A, Arnold D, Hennemann B, Keilholz U: Multicenter phase II study of cetuximab plus docetaxel in 84 patients with recurrent or metastatic, platinum-pretreated SCCHN. J Clin Oncol (Meeting Abstracts) 2009; 27: 6048-.

    Google Scholar 

  65. Gibson MK, Kies M, Kim S, Savvides P, Kotsakis A, Blumenschein G, Worden F, Chen H, Grandis J, Argiris A: Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma: An updated report. J Clin Oncol (Meeting Abstracts) 2009; 27:6049-.

    Google Scholar 

  66. Cohen EE, Davis DW, Karrison TG, Sciwert TY, Wong SJ, Nattam S, Kozloff MF, Clark Jl, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE: Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/I I study. Lancet Oncol 2009; 10: 247–57.

    Article  CAS  PubMed  Google Scholar 

  67. Hough B, Posner M, Chung C, Hainsworth J, Horan J, Chick J, Gibson MK: A phase II study of single agent OSI-7904L in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol (Meeting Abstracts) 2009; 27: e17005-.

    Google Scholar 

  68. Saura C, Baselga J, Herbst R, del Campo J, Marotti M, Tessier J, Collins B, Heymach J: Antitumor activity of cediranib in patients with metastatic or recurrent head and neck cancer (HNC) or recurrent non-small cell lung cancer (NSCLC): An open-label exploratory study. J Clin Oncol (Meeting Abstracts) 2009; 27: 6023-.

    Google Scholar 

  69. Zhao Y, Liao H, Hou X, Sun J, Guo Y, Li S, Zhang L: A prospective, open-label, randomized phase II trial to evaluate the changes of bone résorption marker after administration of zoledronic acid (ZOL) in nasopharyngeal cancer (NPC) patients with bone métastases (BM). J Clin Oncol (Meeting Abstracts) 2009; 27: 6063-.

    Google Scholar 

  70. Cianchetti M, Sandow PS, Scarborough LD, Morris CG, Kirwan J, Werning JW, Mendenhall WM: Radiation therapy for minor salivary gland carcinoma. Laryngoscope 2009; 119:1334–8.

    Article  PubMed  Google Scholar 

  71. Nashed M, Casasola RJ: Biological therapy of salivary duct carcinoma. J Laryngol Otol 2009; 123: 250–2.

    Article  CAS  PubMed  Google Scholar 

  72. Locati LD, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L, Casieri P, Orsenigo M, Losa M, Bergamini C, Liberatoscioli C, Quattrone P, Calderone RG, Rinaldi G, Pilotti S, Licitra L: Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol 2009; 45:574–8.

    Article  CAS  PubMed  Google Scholar 

  73. Grisanti S, Amoroso V, Buglione M, Rosati A, Gatta R, Pizzocaro C, Ferrari VD, Marini G: Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: A case report and review of literature. J Med Case Reports 2008; 2: 320.

    Article  PubMed  Google Scholar 

  74. Dirix P, Vandecaveye V, De Keyzer F, Stroobants S, Hermans R, Nuyts S: Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med 2009; 50: 1020–7.

    Article  PubMed  Google Scholar 

  75. Dirix P, Vandecaveye V, De Keyzer F, Op de Beeck K, Poorten VV, Delaere P, Verbeken E, Hermans R, Nuyts S: Diffusion-Weighted MRI for Nodal Staging of Head and Neck Squamous Cell Carcinoma: Impact on Radiotherapy Planning. Int J Radiat Oncol Biol Phys 2009.

    Google Scholar 

  76. Webster GJ, Kilgallon JE, Ho KF, Rowbottom CG, Slevin NJ, Mackay RI: A novel imaging technique for fusion of high-quality immobilised MR images of the head and neck with CT scans for radiotherapy target delineation. Br J Radiol 2009; 82: 497–503.

    Article  CAS  PubMed  Google Scholar 

  77. Guido A, Fuccio L, Rombi B, Castellucci P, Cecconi A, Bunkheila F, Fuccio C, Spezi E, Angelini AL, Barbieri E: Combined 18F-FDG-PET/CT imaging in radiotherapy target delineation for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 73:759–63.

    Article  PubMed  Google Scholar 

  78. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF: Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008; 49: 480–508.

    Article  PubMed  Google Scholar 

  79. Kyzas PA, Evangelou E, Denaxa-Kyza D, loannidis JP: 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node métastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst 2008; 100: 712–20.

    Article  PubMed  Google Scholar 

  80. Emonts P, Bourgeois P, Lemort M, Flamen P: Functional imaging of head and neck cancers. Curr Opin Oncol 2009; 21: 212–7.

    Article  CAS  PubMed  Google Scholar 

  81. de Bree R, van der Putten L, Brouwer J, Castelijns JA, Hoekstra OS, Leemans CR: Detection of locoregional recurrent head and neck cancer after (chemo)radiotherapy using modern imaging. Oral Oncol 2009; 45: 386–93.

    Article  PubMed  Google Scholar 

  82. Abgral R, Querellou S, Potard G, Le Roux PY, Le Duc-Pennec A, Marianovski R, Pradier O, Bizais Y, Kraeber-Bodere F, Salaun PY: Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med 2009; 50: 24–9.

    Article  PubMed  Google Scholar 

  83. Chua ML, Ong SC, Wee JT, Ng DC, Gao F, Tan TW, Fong KW, Chua ET, Khoo JB, Low JS: Comparison of 4 modalities for distant metastasis staging in endemic nasopharyngeal carcinoma. Head Neck 2009; 31: 346–54.

    Article  PubMed  Google Scholar 

  84. Habermann CR, Gossrau P, Graessner J, Arndt C, Cramer MC, Reitmeier F, Jaehne M, Adam G: Diffusion-weighted echo-planar MRI: a valuable tool for differentiating primary parotid gland tumors? Rofo 2005; 177: 940–5.

    CAS  PubMed  Google Scholar 

  85. Shah GV, Wesolowski JR, Ansari SA, Mukherji SK: New directions in head and neck imaging. J Surg Oncol 2008; 97:644–8.

    Article  PubMed  Google Scholar 

  86. Bisdas S, Baghi M, Smolarz A, Pihno NC, Lehnert T, Knecht R, Mack MG, Vogl TJ, Tuerkay S, Koh TS: Quantitative measurements of perfusion and permeability of oropharyngeal and oral cavity cancer, recurrent disease, and associated lymph nodes using first-pass contrast-enhanced computed tomography studies. Invest Radiol 2007; 42:172–9.

    Article  PubMed  Google Scholar 

  87. Bisdas S, Spicer K, Rumboldt Z: Whole-tumor perfusion CT parameters and glucose metabolism measurements in head and neck squamous cell carcinomas: a pilot study using combined positron-emission tomography/CT imaging. AJNR Am J Neuroradiol 2008; 29:1376–81.

    Article  CAS  PubMed  Google Scholar 

  88. Newbold KL, Partridge M, Cook G, Sharma B, Rhys-Evans P, Harrington KJ, Nutting CM: Evaluation of the role of 18FDG-PET/CT in radiotherapy target definition in patients with head and neck cancer. Acta Oncol 2008; 47:1229–36.

    Article  CAS  PubMed  Google Scholar 

  89. Ahn PH, Garg MK: Positron emission tomography/computed tomography for target delineation in head and neck cancers. Semin Nucl Med 2008; 38:141–8.

    Article  PubMed  Google Scholar 

  90. Deantonio L, Beldi D, Gambaro G, Loi G, Brambilla M, Inglese E, Krengli M: FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma. Radiat Oncol 2008; 3:29.

    Article  PubMed  Google Scholar 

  91. Murakami R, Uozumi H, Hirai T, Nishimura R, Katsuragawa S, Shiraishi S, Toya R, Tashiro K, Kawanaka K, Oya N, Tomiguchi S, Yamashita Y: Impact of FDG-PET/CT fused imaging on tumor volume assessment of head-and-neck squamous cell carcinoma: intermethod and interobserver variations. Acta Radiol 2008; 49: 693–9.

    Article  CAS  PubMed  Google Scholar 

  92. Soto DE, Kessler ML, Piert M, Eisbruch A: Correlation between pretreatment FDG-PET biological target volume and anatomical location of failure after radiation therapy for head and neck cancers. Radiother Oncol 2008.

    Google Scholar 

  93. Tikkakoski T: Impact of FDG-PET/CT fused imaging on tumor volume assessment of head-and-neck squamous cell carcinoma. Acta Radiol 2008; 49:615–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany

    Prof. Dr. Rainald Knecht

Authors
  1. Prof. Dr. Rainald Knecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. HNO-Klinik, Kopf- und Halschirurgie, Universitätsklinikum Erlangen, Waidstraße 1, 91054, Erlangen, Germany

    Heinrich Iro

  2. Universitätsklinikum Gießen und Marburg GmbH HNO-Klinik, Standort Marburg, Deutschhausstraße 3, 35037, Marburg, Germany

    Jochen A. Werner

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag/Wien

About this paper

Cite this paper

Knecht, R. (2009). Onkologie II. In: Stadler, F., Iro, H., Werner, J.A. (eds) Handbuch HNO 2009. Handbuch Update-Seminar. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-05010-7_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-05010-7_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-04987-3

  • Online ISBN: 978-3-642-05010-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation